News | September 18, 2025
Novo Nordisk’s Wegovy delivered 16.6% weight loss
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Maria Soler Nunez appointed as Chief Quality Officer
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Guidelines aim to establish state-regulated veterinary blood banks
Subscribe To Our Newsletter & Stay Updated
